1 / 10

PSYNOVA LTD

PSYNOVA LTD. BIOMARKERS FOR NEUROPSYCHIATRIC CONDITIONS Schizophrenia, bipolar disorder, depression etc. Discovery, validation and exploitation FOUNDED IN 2005 CAMBRIDGE UNIVERSITY SPIN OUT Institute of Biotechnology Cambridge Centre for Neuropsychiatric Research

vangie
Download Presentation

PSYNOVA LTD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PSYNOVALTD • BIOMARKERS FOR NEUROPSYCHIATRIC CONDITIONS • Schizophrenia, bipolar disorder, depression etc. • Discovery, validation and exploitation • FOUNDED IN 2005 • CAMBRIDGE UNIVERSITY SPIN OUT • Institute of Biotechnology • Cambridge Centre for Neuropsychiatric Research • $5M rolling grant: Stanley Medical Research Institute • £2.25M investment: Porton Capital and Cambridge Seed Fund

  2. Dr Sabine Bahn NED Practising Clinical Psychiatrist Director of CCNR Professor Chris Lowe NED Director, IOB 7 Spin-out companies Dr Paul Rodgers Chairman Co-founded 10 biotech companies MD, Ithaka Life Sciences Mrs Shimi Shah NED Porton Capital Mr Bill Matthews NED Cambridge Seed Fund FOUNDERS AND KEY MANAGEMENT

  3. MISSION AND OPPORTUNITY An enormous unmet need… Mental illness accounts for >15% of the burden of disease in established market economies, such as the US (affects 2% of people worldwide) Burden is more than that caused by cancers, respiratory disease, alcohol/drug use, infections and parasitic diseases (WHO) Diagnosis is subjective; current drugs treat symptoms only ($10B market) Psynova intends to: Discover and validate biomarkers for schizophrenia and bipolar disorder Develop new diagnostic and prognostic tests Develop new drugs especially for those patient groups poorly treated by existing drugs

  4. ASSETS Dr BAHN/ CCNR $5M Research Programme (Schizophrenia/Bipolar): Identification of biomarkers 15 Scientists; extensive collaborations RECENT ACHIEVEMENTS Most comprehensive functional genomics study on psychiatric disorders to date First to apply large scale proteomics/NMR techniques Portfolio of over 30 novel biomarkers (growing patent estate) Psynova has exclusive licence to relevant patents and option over future IP CCNR BIOBANK Unique collection of clinical samples (brain/peripheral/biofluids) >500 Schizophrenic/bipolar/major depression/control samples Samples from further 2,000 subjects under negotiation 200 samples from other CNS disorders (Depression/ Alzheimer’s, Down’s, Parkinson’s, Huntingdon’s) Psynova has exclusive access for commercial research purposes PSYFINDERTM Powerful relational database: proprietary data from 150 PM brains Psynova has exclusive access for commercial research purposes

  5. THE PSYFINDERTM DATABASE DATA HANDLING MINING BAYESIAN MODELS VISUALISATION TOOLS IN SILICO EXPERIMENTATION METABOLOMICS/ METANOMICS TRANSCRIPTOMICS LIPIDOMICS PEPTIDOMICS PSYFINDERTM GLYCOMICS METALOMICS CELLULAR/SUBCELLULAR LASER MICRODISSECTION Powerful relational database Proprietary data from 150 PM brains 3 years at a cost of $5M Continuously updated

  6. DISORDERS SCHIZOPHRENIABIPOLAR DISORDER MAJOR DEPRESSION ALZHEIMER’S DOWN’S SYNDROME HUNTINGTON’S DISEASE PARKINSON’S DISEASE SLEEP DEPRIVATION OCD BIOMARKER DISCOVERY PROCESS: Our Strategy p-m BRAIN CSF CNS CSF CSF CSF LIVERSPLEENDURA MATER T-CELLS FIBROBLASTS ERYTHROCYTES WHOLE BLOOD PLASMA SERUM URINE PERIPHERAL TISSUES In order to address questions of disease specificity of a given biomarker it is important to investigate several CNS disorders simultaneously

  7. KEY MILESTONES FOR 2006 • MILESTONES • Confirm potential of lead biomarkers: • Data generation • Clinical samples from healthy volunteers, treated and untreated patients • Generate first revenues: • Fee-for-service or shared risk projects • Grants • Appoint CEO: • Part-time initially • Strengthen advisory team: • Medical, scientific and business consultants

  8. SEEKING DEVELOPMENT PARTNERS • PARTNERSHIPS • Technology providers: • Data generation • Pharmaceutical companies: • Fee-for-service and shared risk projects • Biomarker validation • Clinical development of new products • Re-profiling of old products • Diagnostics companies: • Co-development of diagnostic kits • Chemistry companies: • Screening of libraries for new leads • CRO’s • Pre-clinical and clinical development of NCE’s

  9. SUMMARY Diagnostic tests and effective treatments for schizophrenia and bipolar disorder are major unmet needs Biomarkers are the key to addressing these unmet needs Psynova is developing a strong proprietary position (patents/database/biobank) Revenue generation: Research collaborations with major pharmaceutical companies Diagnostic tests and research assay kits In-house drug discovery – out-license product candidates Series A round: £2M Series B round: £5M Possible exit by trade sale from Year 4 onwards

  10. PSYNOVALTD • CONTACT DETAILS • Dr Paul Rodgers • Psynova Ltd • St John’s Innovation Centre • Cowley Road • Cambridge • CB4 0WS • Tel: 01223 703146 • paul.rodgers@ithaka.co.uk • www.psynova.com (in progress)

More Related